[This corrects the article DOI: 10.1186/1687-9856-2015-4.].

The orally administered PROTAC ER degrader ARV-471 demonstrated potent degradation and tumor growth inhibition, including regression, in preclinical models. In the first-in-human phase I/II study, once-daily (QD) monotherapy was well tolerated showed antitumor activity heavily pretreated patients with ER+/HER2- advanced breast cancer. Anastrozole, an aromatase inhibitor, is a standard treatment...

The orally administered PROTAC ER degrader ARV-471 demonstrated potent degradation and tumor growth inhibition, including regression, in preclinical models. In the first-in-human phase I/II study, once-daily (QD) monotherapy was well tolerated showed antitumor activity heavily pretreated patients with ER+/HER2- advanced breast cancer. Anastrozole, an aromatase inhibitor, is a standard treatment...

A 72-year-old woman 12 years status-post partial mastectomy, adjuvant radiation, and five years of anastrozole for stage I estrogen receptor/progesterone receptor positive breast adenocarcinoma presented with neck pain. MRI showed extensive metastatic disease involving the skull and the vertebral bodies of the cervical and thoracic spine. She was started on dexamethasone. Bone scan revealed mul...